ABSTRACT
The present study aimed to identify the genes associated with the involvement of adjunct lymph nodes of patients with prostate cancer (PCa) and to provide valuable information for the identification of potential diagnostic biomarkers and pathological genes in PCa metastasis. The most important candidate genes were identified through several machine learning approaches including K-means clustering, neural network, Naïve Bayesian classifications and PCA with or without downsampling. In total, 21 genes associated with lymph nodes involvement were identified. Among them, nine genes have been identified in metastatic prostate cancer, six have been found in the other metastatic cancers and four in other local cancers. The amplification of the candidate genes was evaluated in the other PCa datasets. Besides, we identified a validated set of genes involved in the PCa metastasis. The amplification of SPAG1 and PLEKHF2 genes were associated with decreased survival in patients with PCa.
Subject(s)
Antigens, Surface/genetics , Computational Biology/methods , GTP-Binding Proteins/genetics , Lymphatic Metastasis/genetics , Prostatic Neoplasms/pathology , Supervised Machine Learning , Unsupervised Machine Learning , Vesicular Transport Proteins/genetics , Cluster Analysis , Datasets as Topic , Humans , Male , Prostatic Neoplasms/geneticsABSTRACT
MMP-12 belongs to a large family of proteases called matrix metalloproteinases (MMPs) that degrades elastin. The main pathologic role of MMP-12 overexpression was suggested to be associated with pathogenesis mechanism of inflammatory respiratory diseases and atherosclerosis. An integrated ligand- and structure-based virtual screening was employed in hope of finding inhibitors with new scaffolds and selectivity for MMP-12. Seven compounds among 18 experimentally tested compounds had a measurable effect on the inhibition of MMP-12 enzyme. Our results demonstrated the applicability of the developed pharmacophore model and selected crystal structure (PDB code: 3F17) to discover new MMP-12 inhibitors. The receptor structure was selected based on cross-docking results. Here, we report the discovery of new class of MMP-12 inhibitors that could be used for lead optimization. For the inhibition of MMP-12, the significance of its interactions with the catalytic residues Glu219 and Ala182 was emphasized through the inspection of the docking poses.
Subject(s)
Drug Evaluation, Preclinical/methods , Matrix Metalloproteinase 12/metabolism , Matrix Metalloproteinase Inhibitors/chemistry , Matrix Metalloproteinase Inhibitors/pharmacology , Catalytic Domain , Matrix Metalloproteinase 12/chemistry , Matrix Metalloproteinase Inhibitors/metabolism , Molecular Docking Simulation , Structure-Activity Relationship , User-Computer InterfaceABSTRACT
The major histocompatibility complex (MHC) class I-related molecule, MR1, is a key component of the immune system, presenting antigens to T-cell receptors (TCRs) and modulating the immune response against various antigens. MR1 possesses a compact ligand-binding pocket despite its ability to interact with ligands that can have either agonistic or antagonistic effects on the immune system. Agonistic ligands can stimulate the immune response, while antagonistic ligands do not elicit an immune response. In most cases, ligand binding to MR1 is mediated through a covalent bond with Lys43. However, recent studies have suggested that a variety of small molecules can interact with the MR1-binding site. In this study, we have used several approaches to improve the binding pose prediction of covalent ligands to MR1, including docking in mutated receptors, and imposing simple pharmacophore constraints and structural water molecules. The careful assignment of pharmacophore constraints and inclusion of structural water molecules in the challenging docking process of covalent docking improved the binding pose prediction and virtual screening performance. In a retrospective virtual screening, the proposed approach exhibited EF1% and EF2% values of 7.4 and 5.5, respectively. Conversely, when using the mutated receptor, both EF1% and EF2% were recorded as 0 for the conventional docking method. The performance of the pharmacophore constraints was also evaluated on other covalent docking cases, and compared to previously reported results for common covalent docking methods. The proposed approach achieved an average RMSD of 2.55, while AutoDock4, CovDock, FITTED, GOLD, ICM-Pro, and MOE exhibited average RMSD values of 3.0, 2.93, 3.04, 4.93, 2.44, and 3.36, respectively. Our results demonstrate that the inclusion of simple pharmacophore constraints and structural waters can improve the prediction of binding poses of covalent ligands to MR1, which can aid in the discovery of novel immunotherapeutic agents. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-023-03694-w.
ABSTRACT
Introduction: The coronary slow flow phenomenon (CSFP) finding in angiography is characterized by the delayed filling of the terminal vessels without significant epicardial coronary disease. The endothelium performs a vital role in cardiovascular homeostasis by releasing vasoactive substances. Endothelial cells produce nitric oxide (NO) as one of these essential compounds. Three isoforms of nitric oxide synthase (NOS) are endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), and induced nitric oxide synthase (iNOS). We aimed to determine the role of NOS in the development of CSFP as the first human study. Material and methods: A total of 129 patients who met the inclusion criteria were enrolled in the study. The patients were classified into five groups based on the results of coronary angiography: Group 1 without coronary artery disease (CAD) and without CSF, group 2 without CAD and with CSF, group 3 with CAD (< 50%) and without CSF, group 4 with CAD (50-90%) and without CSF, and group 5 with CAD and CSF. The serum level of NOS was determined in the participants. Coronary flow was quantified in patients with CSFP using the corrected TIMI frame count (CTFC) method, and the correlation between the levels of this biomarker and CTFC was investigated. Results: In this study, the NOS serum levels were not significantly correlated with the mean CTFC. Since the total amount of NOS was measured as a result of 3 isoforms of this enzyme, the lack of correlation could be related to increased iNOS level and decreased eNOS concentration. Conclusions: These results should be confirmed by more human studies.
ABSTRACT
CONTEXT AND OBJECTIVE: Increased level of inflammatory mediators plays a central role in the features of coronary artery diseases (CAD). As pentoxifylline could suppress the inflammatory process and has shown some promising beneficial effects in inflammatory diseases, we evaluated the effect of 2 months pentoxifylline administration in patients with CAD. MATERIALS AND METHODS: A randomized placebo-controlled double-blind study design was used. Forty CAD patients (32 males and 8 females) were randomized into either 2 months of pentoxifylline treatment (1200 mg/day) (n = 20) or placebo treatment (n = 20). Blood samples were obtained before and after treatment. Gene expression analysis for mRNA of CD40, p65 and IκBα in peripheral blood mononuclear cells (PBMCs) were performed using real-time reverse-transcription polymerase chain reaction (RT-PCR). Plasma concentration of soluble CD40 (sCD40) ligand as well as protein concentration of p50 were measured by ELISA method. RESULTS: Pentoxifylline decreased CD40 mRNA by 45% (p < 0.05) in PBMCs and sCD40 ligand level in plasma of CAD patients by 34% (p < 0.01). DISCUSSION AND CONCLUSION: Pentoxifylline treatment can suppress the CD40/CD40 ligand system activation in CAD patients. As this system has a role in plaque progression and plaque rupture, pentoxifylline could be a good choice for future studies in preventing cardiovascular events.
Subject(s)
CD40 Antigens/biosynthesis , Coronary Artery Disease/blood , Coronary Artery Disease/drug therapy , Gene Expression Regulation/drug effects , Pentoxifylline/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , CD40 Ligand/biosynthesis , Double-Blind Method , Female , Humans , I-kappa B Proteins/biosynthesis , Male , Middle Aged , RNA, Messenger/biosynthesis , Transcription Factor RelA/biosynthesisABSTRACT
OBJECTIVE: It has been shown previously that the serum level of F2-isoprostanes acts as an indicator of oxidative stress, which is a risk factor for vascular disease especially in end-stage renal disease. It is not known whether n-3 polyunsaturated fatty acids can decrease oxidative stress in renal recipient patients. DESIGN, SETTING, AND SUBJECTS: In this single blind, randomized, placebo-controlled study, the effect of 3 and 6 months of fish oil administration on 8-isoprostane levels in renal transplant recipients was evaluated. INTERVENTION: Twenty-two renal transplant patients who fulfilled inclusion and exclusion criteria randomly received either fish oil dietary supplementation, 6 g/day (720 mg of DHA and 1,080 mg of EPA) or placebo for 6 months. MAIN OUTCOME MEASURE: Serum 8-isoprostane concentration was measured as markers of oxidative stress. RESULTS: A significant decrease in 8-isoprostane levels was observed only in the placebo group after transplantation compared to baseline (P < 0.05). However, the group receiving fish oil had a significantly lower cholesterol level than that of the placebo group (P < 0.05). CONCLUSION: On the basis of our results, omega-3 fatty acids supplementation decreased the beneficial effects of kidney transplantation on oxidative stress.
Subject(s)
F2-Isoprostanes/blood , Fatty Acids, Omega-3/metabolism , Fish Oils/administration & dosage , Kidney Failure, Chronic/therapy , Kidney Transplantation , Adult , Dinoprost/analogs & derivatives , Female , Humans , Male , Middle Aged , Oxidative Stress , Risk Factors , Single-Blind Method , Young AdultABSTRACT
AIMS AND BACKGROUND: The prognosis of glioblastoma multiforme (GBM) remains poor despite advances in surgery and adjuvant therapies. TP53 and O6-methylguanine-DNA methyltransferase (MGM) are tumor suppressor genes that are implicated in GBM resistance to radiation and chemotherapy. In order to assess the expression of the protein products of these two genes, 50 GBM samples were analyzed in this study. METHODS: Demographic and clinical data along with postsurgery tumor samples from 50 GBM patients were collected from the pathology archive. MGMT and p53 protein expression was evaluated by immunohistochemistry. RESULTS: 52% of cases had mutated p53, predominantly expressed in the nuclei of tumor cells. MGMT immunohistochemistry was negative in 35 (70%) patients and positive in 15 (30%) others. Immunohistochemistry-negative specimens for MGMT expression showed a significantly higher expression of mutant p53 (P = 0.03). CONCLUSION: MGMT expression was significantly lower in cells bearing p53 mutation. This indicates that there is a tendency for p53 activity to decline with MGMT inactivation. However, this study could not deduce which protein was the regulator of the other.
Subject(s)
Brain Neoplasms/enzymology , Brain Neoplasms/genetics , DNA Modification Methylases/metabolism , DNA Repair Enzymes/metabolism , Glioblastoma/enzymology , Glioblastoma/genetics , Mutation , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Proteins/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Brain Neoplasms/ethnology , Female , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Glioblastoma/ethnology , Humans , Immunohistochemistry , Iran/epidemiology , Male , Middle Aged , Predictive Value of Tests , PrognosisABSTRACT
Machine learning (ML) method performances, including deep learning (DL) on a diverse set with or without feature selection (FS), were evaluated. The superior performance of DL on small sets has not been approved previously. On the other hand, the available sets for the newly identified targets usually are limited in terms of size. It was explored whether the FS, hyperparameters search, and using ensemble model are able to improve the ML and DL performance on the small sets. The QSAR classifier models were developed using K-nearest (KN) neighbors, DL, random forest (RF), naïve Bayesian (NB) classification, support vector machine (SVM), and logistic regression (LR). Generally, the best individual performers were DL and SVM. The LR had a similar performance to the DL and SVM on the small subsets. The nested cross-validation method was able to include different feature vectors in combination with different ML methods to generate an ensemble model for the datasets with similar performance to the best performers. The general performance for the baseline NB model was Matthews correlation coefficient = 0.356, and it was improved to around 0.66 and 0.63 by NB assisted FS with subsequent SVM/DL classification and an ensemble model, respectively.
Subject(s)
Machine Learning , Bayes Theorem , Logistic Models , Quantitative Structure-Activity Relationship , Support Vector MachineABSTRACT
Due to the high frequency and mortality of breast cancer, developing efficient targeted drug delivery systems for frightening against this malignancy is among cancer research priorities. The aim of this study was to synthesize a targeted micellar formulation of docetaxel (DTX) using DTX, folic acid (FA) and polyethylene glycol (PEG) conjugates as building blocks. In the current study, two therapeutic polymers consisting of FA-PEG-DTX and PEG-DTX conjugates were synthesized and implemented to form folate-targeted and non-targeted micelles. Dissipative particle dynamics (DPD) method was used to simulate the behavior of the nanoparticle. The anti-cancer drug, DTX was loaded in to the micelles via solvent switching method in order to increase its solubility and stability. The cytotoxicity of the targeted and non-targeted formulations was evaluated against 4T1 and CHO cell lines. In vivo therapeutic efficiency was studied using ectopic tumor model of metastatic breast cancer, 4T1, in Female BALB/c mice. The successful synthesis of therapeutic polymers, FA-PEG-DTX and PEG-DTX were confirmed implementing 1HNMR spectral analysis. The size of DTX-loaded non-targeted and targeted micelles were 176.3 ± 8.3 and 181 ± 10.1 nm with PDI of 0.23 and 0.17, respectively. Loading efficiencies of DTX in non-targeted and targeted micelles were obtained to be 85% and 82%, respectively. In vitro release study at pH = 7.4 and pH = 5.4 showed a controlled and continuous drug release for both formulations, that was faster at pH = 5.4 (100% drug release within 120 h) than at pH = 7.4 (80% drug release within 150 h). The targeted formulation showed a significant higher cytotoxicity against 4T1 breast cancer cells (high expression of folate receptor) within the range of 12.5 to 200 µg/mL in comparison with no-targeted one. However, there was no significant difference between the cytotoxicity of the targeted and non-targeted formulations against CHO cell line as low-expressed cell line. In accordance with in vitro investigation, in vivo studies verified the ideal anti-tumor efficacy of the targeted formulation compared to Taxotere and non-targeted formulation. Based on the obtained data, FA-targeted DTX-loaded nano-micelles significantly increased the therapeutic efficacy of DTX and therefore can be considered as a new potent platform for breast cancer chemotherapy.
Subject(s)
Antineoplastic Agents , Breast Neoplasms , Animals , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Cell Line, Tumor , Docetaxel , Drug Carriers/therapeutic use , Female , Folic Acid/therapeutic use , Humans , Mice , Mice, Inbred BALB C , Micelles , Polyethylene Glycols/therapeutic useABSTRACT
Chronic inflammation in dialysis patients increases the production of cytokines such as TNF-α, IL-1ß and IFN- IFN-γ and there is evidence of a significant mortality rate in dialysis patients due to inflammation. Overproduction of inflammatory cytokines can induce complications such as atherosclerosis, malnutrition and anaemia, which are mostly resistant to erythropoietin treatment. Cardiovascular disease is the leading cause of death in haemodialysis patients and about half of the mortality is attributable to cardiovascular disease. Silymarin modulates the immune system by inhibition of neutrophil immigration, mast cell immobilization, prostaglandin production and leukotriene synthesis. Furthermore, silymarin suppresses the induction of TNF-α and it was hypothesized that silymarin could decrease the serum concentration of TNF-α in peritoneal dialysis patients, and thus treat anaemia. Fifteen peritoneal dialysis patients were enrolled in this study and serum levels of soluble TNF-α were measured using an enzyme-linked immunosorbant assay (ELISA) kit. Serum TNF-α was found to be decreased in some patients and in the response group, the haemoglobin concentration after 8 weeks of silymarin administration was increased significantly (p < 0.05). Based on the results of this study, it is suggested that silymarin may be useful in the treatment of inflammation for peritoneal dialysis patients.
Subject(s)
Inflammation/drug therapy , Peritoneal Dialysis , Silymarin/therapeutic use , Tumor Necrosis Factor-alpha/blood , Aged , Enzyme-Linked Immunosorbent Assay , Female , Hemoglobins/analysis , Humans , Male , Middle Aged , Tumor Necrosis Factor-alpha/drug effectsABSTRACT
[This corrects the article DOI: 10.1155/2020/4592190.].
ABSTRACT
O(6)-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that removes alkyl groups from the O(6) position of guanine. MGMT is transcriptionally silenced by promoter hypermethylation in several human neoplasia. We used methylation-specific PCR (MSP) to analyze the MGMT promoter methylation status of 50 glioblastoma tumors. Hypermethylation was detected in 24 of 50 (48%) samples. We also analyzed mutant p53 expression by immunohistochemical analysis of glioblastoma tissue samples. A significant association was found between MGMT methylation and p53 mutation status (p< .05). These results suggested that epigenetic inactivation of MGMT plays an important role in the survival of glioblastoma patients and this inactivated gene involved in p53 mutation.
Subject(s)
Brain Neoplasms/genetics , CpG Islands , DNA Methylation , DNA Modification Methylases/genetics , DNA Repair Enzymes/genetics , Glioblastoma/genetics , Mutation , Promoter Regions, Genetic , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Proteins/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Brain Neoplasms/chemistry , Brain Neoplasms/enzymology , Child , Gene Expression Regulation, Neoplastic , Glioblastoma/chemistry , Glioblastoma/enzymology , Humans , Immunohistochemistry , Iran , Middle Aged , Polymerase Chain Reaction , Tumor Suppressor Protein p53/analysis , Young AdultABSTRACT
5-Alpha-reductase 2 is an interesting pharmaceutical target for the treatment of several diseases, including prostate cancer, benign prostatic hyperplasia, male pattern baldness, acne, and hirsutism. One of the main approaches in computer aided drug design is structure-based drug discovery. However, the experimental 3D structure of 5-alpha-reductase 2 is not available at present. Therefore, a homology modeling method and molecular dynamics simulation were used to develop a reliable model of 5-alpha-reductase 2 for inhibitor pose prediction and virtual screening. Despite the low sequence identity between the target and template sequences, a useful 3D model of 5-alpha-reductase 2 was generated by the inclusion of experimental data.
Subject(s)
3-Oxo-5-alpha-Steroid 4-Dehydrogenase/chemistry , Drug Discovery , Molecular Dynamics Simulation , Catalytic Domain , Computer Simulation , Finasteride/pharmacology , Humans , Models, Chemical , NADP/pharmacology , Oxidation-Reduction , Protein Binding , Protein ConformationABSTRACT
BACKGROUND: The Soluble Epoxide Hydrolase (sEH) is a ubiquitously expressed enzyme in various tissues. The inhibition of the sEH has shown promising results to treat hypertension, alleviate pain and inflammation. OBJECTIVE: In this study, the power of machine learning has been employed to develop a predictive QSAR model for a large set of sEH inhibitors. METHODS: In this study, the random forest method was employed to make a valid model for the prediction of sEH inhibition. Besides, two new methods (Treeinterpreter python package and LIME, Local Interpretable Model-agnostic Explanations) have been exploited to explain and interpret the model. RESULTS: The performance metrics of the model were as follows: R2=0.831, Q2=0.565, RMSE=0.552 and R2 pred=0.595. The model also demonstrated good predictability on the two extra external test sets at least in terms of ranking. The Spearman's rank correlation coefficients for external test set 1 and 2 were 0.872 and 0.673, respectively. The external test set 2 was a diverse one compared to the training set. Therefore, the model could be used for virtual screening to enrich potential sEH inhibitors among a diverse compound library. CONCLUSION: As the model was solely developed based on a set of simple fragmental descriptors, the model was explained by two local interpretation algorithms, and this could guide medicinal chemists to design new sEH inhibitors. Moreover, the most important general descriptors (fragments) suggested by the model were consistent with the available crystallographic data. The model is available as an executable binary at http://www.pharm-sbg.com and https://github.com/shamsaraj.
Subject(s)
Algorithms , Enzyme Inhibitors/chemistry , Databases, Factual , Enzyme Inhibitors/pharmacology , Epoxide Hydrolases/antagonists & inhibitors , Epoxide Hydrolases/metabolism , High-Throughput Screening Assays , Machine Learning , Models, Molecular , Molecular Structure , Quantitative Structure-Activity Relationship , SolubilityABSTRACT
BACKGROUND: In this study, the effects of three structural analogues of adenosine upon proliferation of human tumor cells were investigated. Previous research showed a cytotoxic effect of adenosine via A3 receptor and A1 receptor and sometimes this effect was receptor independent. The researches showed a differential cytotoxic effect of adenosine and its A3 agonists on cancerous cells, while other studies demonstrated tumor promoting effect of adenosine and its A1 agonists. The purpose of the present study was the evaluation of the possible selective anti-tumor effect of A1 receptor agonists on cancerous cells. METHODS: The substances of N6-cyclohexyl-adenosine (CHA, A1 agonist), R-isomer of N6 phenylisopropyladenosine (R-PIA, A1 agonist) and N5-eethylcarboxamido-adenosine (NECA, adenosine A1-A2 non-specific agonist) were tested for their anti-proliferative effect using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay method. Hep G2, Hep2, CACO2, ACHN and L929 cell lines were used in this assay. RESULTS: CHA inhibited cell proliferation in three cell lines (in concentration of 5-50 microM) and R-isomer of R-PIA in one cell line (in concentration of 10-50 microM). These effects were inhibited partially by addition of 1,3-Dipropyl-8-cyclopentylxanthine (A1 antagonist). The NECA analogue had no inhibitory effect on the cell proliferations. All of the substances had no cytotoxic effect on L929 cells (mouse connective tissue fibroblast cell line). CONCLUSION: CHA and R-PIA had inhibitory effect on the proliferation of human tumor cell lines partially via A1 receptor, while they didn't show such effect on fibroblast cells. These results suggest that A1 adenosine receptor agonist have a good potential of specific anti-tumor activity.
Subject(s)
Adenosine A1 Receptor Agonists , Adenosine-5'-(N-ethylcarboxamide)/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Humans , Methotrexate/pharmacology , Receptor, Adenosine A1/metabolismABSTRACT
MMP-2 belongs to a large family of proteases called matrix metalloproteinases (MMPs) that degrades type IV collagen, the main structural component of basement membranes and gelatin. The main pathologic role of MMP-2 overexpression is to contribute to the development of cancer through the progression of metastasis and angiogenesis. A structure-based virtual screening was employed to find new inhibitors with possible selectivity for MMP-2. The inhibitory activities of 3 inhibitors (one was not a suitable drug-like hit) among 19 purchased compounds were approved by enzyme inhibition assay. 5 hits were non-zinc-binding inhibitors of MMP-2. The results demonstrated that a computer-aided drug design could be successfully applied for discovering new MMP-2 inhibitors. We found inhibitors with new scaffolds for the inhibition of MMP-2 with some selectivity features that could be used for future lead optimization processes. According to the docked pose and MD simulation, compound 13 was expected to interact with the S1' specificity loop of MMP-2 and had 2 π-π interactions and a stable hydrogen bond with the MMP-2 active site. The key feature of compound 13 could be used to guide the design of new non-zinc-binding inhibitors of MMP-2.
Subject(s)
Drug Evaluation, Preclinical , Matrix Metalloproteinase 2/chemistry , Matrix Metalloproteinase Inhibitors/pharmacology , Catalytic Domain , Drug Design , Drug Discovery , Molecular Dynamics Simulation , ZincABSTRACT
Rescoring is a simple approach that theoretically could improve the original docking results. In this study AutoDock Vina was used as a docked engine and three other scoring functions besides the original scoring function, Vina, as well as their combinations as consensus scoring functions were employed to explore the effect of rescoring on virtual screenings that had been done on diverse targets. Rescoring by DrugScore produces the most number of cases with significant changes in screening power. Thus, the DrugScore results were used to build a simple model based on two binding site descriptors that could predict possible improvement by DrugScore rescoring. Furthermore, generally the screening power of all rescoring approach as well as original AutoDock Vina docking results correlated with the Maximum Theoretical Shape Complementarity (MTSC) and Maximum Distance from Center of Mass and all Alpha spheres (MDCMA). Therefore, it was suggested that, with a more complete set of binding site descriptors, it could be possible to find robust relationship between binding site descriptors and response to certain molecular docking programs and scoring functions. The results could be helpful for future researches aiming to do a virtual screening using AutoDock Vina and/or rescoring using DrugScore.
ABSTRACT
BACKGROUND: Quantitative Structure Activity Relationship (QSAR) is a difficult computational chemistry approach for beginner scientists and a time consuming one for even more experienced researchers. METHOD AND MATERIALS: Ezqsar which is introduced here addresses both the issues. It considers important steps to have a reliable QSAR model. Besides calculation of descriptors using CDK library, highly correlated descriptors are removed, a provided data set is divided to train and test sets, descriptors are selected by a statistical method, statistical parameter for the model are presented and applicability domain is investigated. RESULTS: Finally, the model can be applied to predict the activities for an extra set of molecules for a purpose of either lead optimization or virtual screening. The performance is demonstrated by an example. CONCLUSION: The R package, ezqsar, is freely available via https://github.com/shamsaraj/ezqsar, and it runs on Linux and MS-Windows.
ABSTRACT
AIM AND OBJECTIVE: MMP-13 belongs to a large family of proteases called matrix metalloproteinases (MMPs) that degrades type II collagen, the main structural protein of articular cartilage. The main pathologic role of MMP-13 over expression is to contribute to the development of osteoarthritis. METHODS: To find new inhibitors with possible selectivity for MMP-13 a structure based virtual screening was employed. The inhibitory activities of 11 inhibitors among 19 purchased compounds were approved by enzyme inhibition assay. RESULTS: Our results demonstrated that the CADD (computer aided drug design) could be successfully applied to find new MMP-13 inhibitors using a receptor structure (PDB code: 3O2X) which had been demonstrated a good performance in a cross-docking study. CONCLUSION: We discovered inhibitors with new scaffolds for inhibition of MMP-13 and some selectivity features such as proper S1' occupancy and interactions with S1' pocket that could be subjected to a future lead optimization study.
Subject(s)
Drug Evaluation, Preclinical/methods , Matrix Metalloproteinase 13/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Humans , Matrix Metalloproteinase Inhibitors/chemistry , Molecular Docking Simulation , Molecular Structure , Structure-Activity RelationshipABSTRACT
BACKGROUND: Dissipative particle dynamics (DPD) is a simulation method that has one of its applications in the field of pharmaceutical science and drug delivery. OBJECTIVE: DPD is employed to study morphology and some other characteristics of polymeric nanomicelles. Two systems were considered in this study: system A which includes curcumin, Polycaprolactone (PCL), Polyethylene glycol (PEG) and water beads and system B which includes paclitaxel, Polylactic acid (PLA), PEG and water beads. METHOD: In this study we focused on the simulation of drug entrapment in polymeric micelles using DPD method. RESULTS: Results indicated that the qualitative comparison of polymeric-micelles with different compositions, after carefully tuning input parameters and simulation conditions, can be successfully performed using DPD. CONCLUSION: Considering real state of a system for DPD simulation will have a great impact on the reliability of the simulation results.